tetano
Editor, Senior Moderator
Gene
. 2020 Dec 17;145368.
doi: 10.1016/j.gene.2020.145368. Online ahead of print.
Recognition of Plausible Therapeutic Agents to Combat COVID-19: An Omics Data Based Combined Approach
Mohammad Uzzal Hossain[SUP] 1 [/SUP], Arittra Bhattacharjee[SUP] 2 [/SUP], Md Tabassum Hossain Emon[SUP] 3 [/SUP], Zeshan Mahmud Chowdhury[SUP] 4 [/SUP], Md Golam Mosaib[SUP] 5 [/SUP], Muntahi Mourin[SUP] 4 [/SUP], Keshob Chandra Das[SUP] 6 [/SUP], Chaman Ara Keya[SUP] 4 [/SUP], Md Salimullah[SUP] 7 [/SUP]
Affiliations
Abstract
Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has become an immense threat to global public health. In this study, more than 67,000 reference sequences including a complete genome sequence of SARS-CoV-2 isolate performed by us and several in silico techniques were merged to propose prospective therapeutics. Through meticulous analysis, several conserved and therapeutically suitable regions of SARS-CoV-2 such as RNA-dependent RNA polymerase (RdRp), Spike (S) and Membrane glycoprotein (M) coding genes were selected. Both S and M were chosen for the development of a chimeric vaccine that can generate memory B and T cells. siRNAs were also designed for S and M gene silencing. Moreover, six new drug candidates were suggested that might inhibit the activity of RdRp. Since SARS-CoV-2 and SARS-CoV-1 have 82.30% sequence identity, a Gene Expression Omnibus (GEO) dataset of Severe Acute Respiratory Syndrome (SARS) patients were analyzed. In this analysis, 13 immunoregulatory genes were found that can be used to develop type 1 interferon (IFN) based therapy. The proposed vaccine, siRNAs, drugs and IFN based analysis of this study will accelerate the development of new treatments.
Keywords: COVID-19; Interferons; SARS-CoV-2; chimeric vaccine; genome sequencing; siRNAs; small molecule drugs.
. 2020 Dec 17;145368.
doi: 10.1016/j.gene.2020.145368. Online ahead of print.
Recognition of Plausible Therapeutic Agents to Combat COVID-19: An Omics Data Based Combined Approach
Mohammad Uzzal Hossain[SUP] 1 [/SUP], Arittra Bhattacharjee[SUP] 2 [/SUP], Md Tabassum Hossain Emon[SUP] 3 [/SUP], Zeshan Mahmud Chowdhury[SUP] 4 [/SUP], Md Golam Mosaib[SUP] 5 [/SUP], Muntahi Mourin[SUP] 4 [/SUP], Keshob Chandra Das[SUP] 6 [/SUP], Chaman Ara Keya[SUP] 4 [/SUP], Md Salimullah[SUP] 7 [/SUP]
Affiliations
- PMID: 33346100
- DOI: 10.1016/j.gene.2020.145368
Abstract
Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has become an immense threat to global public health. In this study, more than 67,000 reference sequences including a complete genome sequence of SARS-CoV-2 isolate performed by us and several in silico techniques were merged to propose prospective therapeutics. Through meticulous analysis, several conserved and therapeutically suitable regions of SARS-CoV-2 such as RNA-dependent RNA polymerase (RdRp), Spike (S) and Membrane glycoprotein (M) coding genes were selected. Both S and M were chosen for the development of a chimeric vaccine that can generate memory B and T cells. siRNAs were also designed for S and M gene silencing. Moreover, six new drug candidates were suggested that might inhibit the activity of RdRp. Since SARS-CoV-2 and SARS-CoV-1 have 82.30% sequence identity, a Gene Expression Omnibus (GEO) dataset of Severe Acute Respiratory Syndrome (SARS) patients were analyzed. In this analysis, 13 immunoregulatory genes were found that can be used to develop type 1 interferon (IFN) based therapy. The proposed vaccine, siRNAs, drugs and IFN based analysis of this study will accelerate the development of new treatments.
Keywords: COVID-19; Interferons; SARS-CoV-2; chimeric vaccine; genome sequencing; siRNAs; small molecule drugs.